TiumBio Co Ltd
KOSDAQ:321550
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
TiumBio Co Ltd
Operating Expenses
TiumBio Co Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
TiumBio Co Ltd
KOSDAQ:321550
|
Operating Expenses
-₩25.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Operating Expenses
-₩1.3T
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-26%
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Operating Expenses
-₩36.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Operating Expenses
-₩58.7B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-33%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Operating Expenses
-₩119.7B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Operating Expenses
-₩36.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
TiumBio Co Ltd
Glance View
TiumBio Co., Ltd. engages in the development and manufacture of therapeutic drugs. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2019-11-22. The firm researches and develops small molecule drugs including endometriosis treatments, uterine fibroids treatments, cancer immunotherapy drugs; and new biopharmaceuticals including hemophilia treatments, and others.
See Also
What is TiumBio Co Ltd's Operating Expenses?
Operating Expenses
-25.5B
KRW
Based on the financial report for Dec 31, 2024, TiumBio Co Ltd's Operating Expenses amounts to -25.5B KRW.
What is TiumBio Co Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-23%
Over the last year, the Operating Expenses growth was 22%. The average annual Operating Expenses growth rates for TiumBio Co Ltd have been 8% over the past three years , -23% over the past five years .
